.jpg)
"Mid-sized CROs like Linical can be suitable partners for relatively small pharmaceutical and biotech companies that are searching for flexibility and true collaboration."
Dr Toshiaki Nagafuji leads the Innovative Drug Development Business (IDDB) at Linical after a career spanning discovery and research at Chugai and clinical development, project management, and business development at Shionogi. At Chugai, he also served as a visiting professor at Brain Research Institute, Niigata University and a visiting researcher at University of California San Francisco. At Shionogi, he also worked at its US subsidiary in New Jersey. With experience in both Japan and the US, he shares insights on Japan’s evolving regulatory landscape, the rising complexity of cell and gene therapy trials, and Linical’s positioning against global CROs.
Before we discuss Linical specifically, could you give us a sense of where Japan sits in the global clinical trial landscape today, and how you see that picture changing?
"According to a report, in 2025 clinical trials conducted by companies headquartered in Japan accounted for only 4% of all clinical trials conducted worldwide. US companies ranked first (35%), followed by Chinese companies (32%) and European companies (20%). European companies held the top spot globally in 2009 with a share exceeding 40%, but their share has been declining steadily since then. Japanese companies held a share exceeding 10% until 2014, but this has been gradually decreasing."
Read the full interview by clicking the link below.
This article is taken from pharmaboardroom.com 28.05.26
References:
1. Visit: pharmaboardroom.com